The modern sedentary lifestyle is contributing to an increase in obesity and cardiovascular disease, which is expected to fuel the market for point-of-care cholesterol monitoring devices. Cardiovascular diseases are primarily caused by physical inactivity. Almost every aspect of society is being impacted. The demand for point-of-care cholesterol monitoring devices is anticipated to rise due to the widespread incidence of cardiovascular diseases. The market for point-of-care cholesterol monitoring devices is predicted to see tremendous growth opportunities as a result of the increasing demand for these devices. The preference for daily disease monitoring and self-testing has led to a rise in the use of point-of-care cholesterol monitoring devices.
The World Health Organization (WHO) estimates that nearly 17.9 million people worldwide pass away from cardiovascular diseases each year, accounting for 31% of all global fatalities. The increasing prevalence of heart attacks, hypertension, and strokes is another factor that is anticipated to drive up demand for point-of-care cholesterol monitoring devices.
Governmental organisations now organise numerous awareness campaigns to manage and prevent high cholesterol. For instance, the CDC (Centre for Disease Control and Prevention) runs the National Heart Disease and Stroke Prevention Program and Lipid Standardization Program to raise awareness among the populace. To raise awareness of the negative effects of cholesterol, these programmes run trainings, campaigns, and educational sessions for hospital staff members. The trend toward healthy eating and living has grown in recent years as a result of numerous government initiatives, such as campaigns that increased the adoption of devices for cholesterol self-testing, which grew the market for point-of-care cholesterol monitoring devices over the forecast period.
According to the CDC (Center for Disease Control and Prevention), 55% of American adults, or more than half the population, take medication for health issues related to high cholesterol. Thus, it is anticipated that the global point-of-care cholesterol monitoring device market will grow as a result of the increasing prevalence of cardiovascular diseases and their complications caused by high cholesterol.
Point-of-care monitoring tools are beneficial in urgent situations where quick access to test results is necessary for clinical judgement. But there are numerous difficulties with POCT, mostly in the area of quality control. In accordance with GLP (Good Laboratory Practices), trained professionals perform the tests in laboratories, and specific precautions are taken to ensure that patients receive immediate results.
The point-of-care cholesterol monitoring device market has been divided by product type, technology, application, end user, and geographical regions by the company. The point-of-care cholesterol monitoring device market has been divided into point-of-care instruments and testing kits based on the type of product. In the market for point-of-care cholesterol monitoring devices, the testing kit segment is anticipated to account for a sizable share. The company claims that in 2017, the testing kit market had a revenue share of over 60% of the market for point-of-care cholesterol monitoring devices worldwide.
The market for point-of-care cholesterol monitoring devices has been divided geographically into the following regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China & Japan, China, Japan, and MEA. The region with the largest revenue share in the global point-of-care cholesterol monitoring device market is predicted to be North America, followed by Asia Pacific. In emerging markets like MEA and APECJ, many local players in Japan are concentrating on growing their market share.
The point-of-care cholesterol monitoring device market is divided into hospitals, diagnostic and laboratory facilities, ambulatory surgical centres, and home care settings based on end users. The market for point-of-care cholesterol monitoring devices is anticipated to be dominated by the diagnostic centre & laboratory segment.
The company’s report tracks some of the key companies operating in the point-of-care cholesterol monitoring device market, which include F. Hoffmann-La Roche Ltd., Acon Laboratories, Inc., Abaxis, Inc., Abbott Laboratories, SD Biosensor, Inc., Jant Pharmacal Corporation, DiaSys Diagnostic Systems GmbH, Bioptik Ltd., and Fitech UK Ltd., among others.
Point-of-care Cholesterol Monitoring Device Market by Category
- Table-top Analyzers
- Hand-held Analyzers
- Testing Kits
- Electrochemical Biosensor
- Reflectance Photometry
By End User
- Diagnostics centers & Laboratory
- Ambulatory surgical centers
- Home care sittings
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific excluding China & Japan (APECJ)
- Middle East and Africa (MEA)